For anyone in Podor looking to source CJC-1295, the foundational reality is that this compound moves through online research channels. This matters because CJC-1295 quality varies dramatically across the market — from pharmaceutical-grade 99%+ purity to mislabeled or underdosed compounds — and the vendor is the entire quality system. A legitimate CJC-1295 supplier's COA should include HPLC purity, mass spectrometry confirmation of molecular identity, bacterial endotoxin testing, and a residual solvents panel — all corresponding to the vial you receive. This guide gives Podor researchers the framework to assess vendor quality rigorously and source high-purity CJC-1295 with confidence.
CJC-1295: What the Research Shows
The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Podor researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.
CJC-1295 Purchasing Guide
Before assessing any particular supplier, establish a quality benchmark — so you can identify whether a supplier meets the standard. Endotoxin testing in the COA is critical for any injectable research use — endotoxins from microbial contamination can trigger serious immune reactions even at trace quantities. Warning signs in CJC-1295 vendor evaluation: prices far under typical market pricing, unclear production details, no community presence, and COAs that lack endotoxin data. The lyophilised (freeze-dried) form of CJC-1295 is much more stable than liquid pre-made solutions — lyophilised powder stays viable for years at −20°C, while liquid preparations degrade within weeks even when refrigerated.
Order CJC-1295 — ships to Podor
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not undergone the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Reconstitute CJC-1295 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg reconstituted in 2mL produces 2.5mg/mL — or 25mcg per insulin syringe unit. The main safety concern arising from sourcing in CJC-1295 research is endotoxin contamination from poor sourcing — a documented endotoxin result in your specific batch certificate is the direct mitigation for this hazard. The research literature on CJC-1295 should be reviewed carefully before beginning any research — study methodologies, dosing, and endpoints vary significantly and not all findings translate directly.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
